(-)-Epigallocatechin Gallate

PubMed: 28443100      Front Immunol

Human primary macrophages derived from peripheral blood mononuclear cells (PBMCs) cultured with autologous serum were pretreated with EGCG (50 μg/mL) for 30 min and exposed to LPS (200 EU/mL) for 3 h. Cell lysates from time course experiments of EGCG treatment were analyzed by western blotting and probed with a Notch1/2 antibody  

PubMed: 30233784      Biomed Rep

Effects of EGCG on IGF-I-induced phosphorylation of (A) p44/p42 MAP kinase in MC3T3-E1 cells. The cells were pretreated with various doses of EGCG for 60 min, and then stimulated by 10 nM IGF-I or vehicle for (A) 5 min. Western blot analysis was performed using antibodies against phospho-p44/p42 MAP kinase, p44/p42 MAP kinase. The histograms show quantitative representation of the levels of IGF-I-induced phosphorylation determined from laser densitometric analysis of three independent experiments. EGCG, (−)-epigallocatechin gallate; IGF-I, insulin-like growth factor-I; MAP, mitogen-activated protein.

PubMed: 28693189      Oncol Lett

EGCG inhibits β-catenin, p-Akt and cyclin D1 expression in MDA-MB-231 cells. MDA-MB-231 cells were treated with EGCG for 24 h. (A) β-catenin protein expression was analyzed by western blotting. (B) p-Akt and cyclin D1 protein expression were analyzed by western blotting. β-actin was used as a loading control. Each value represents the mean ± standard error of the mean of three independent experiments. EGCG, epigallocatechin gallate; p-, phosphorylated.

PubMed: 28693189      Oncol Lett

Effect of EGCG on the viability of MDA-MB-231 cells. MDA-MB-231 cells were treated with various concentrations of EGCG for 24 h. MTT assay was used to detect the viability of the cells. The optical density value of the untreated cells was regarded as 100%. Each value represents the mean ± standard error of the mean of three independent experiments. EGCG, epigallocatechin gallate.

PubMed: 23525843      Onco Targets Ther

The percent EGCG that inhibits the proliferation of colorectal cancer cells at different concentrations. Notes: The x-axis and y-axis are the time after treatment and percentage of EGCG that inhibits the proliferation of colorectal cancer cells at different concentrations. Eight experiments were performed for each treatment, and the inhibition rate of cell proliferation was tested for, using a single factor analysis of variance. Abbreviation: EGCG, epigallocatechin gallate; h, hour.